|
US3989816A
(en)
*
|
1975-06-19 |
1976-11-02 |
Nelson Research & Development Company |
Vehicle composition containing 1-substituted azacycloheptan-2-ones
|
|
US4405616A
(en)
|
1975-06-19 |
1983-09-20 |
Nelson Research & Development Company |
Penetration enhancers for transdermal drug delivery of systemic agents
|
|
US4316893A
(en)
|
1975-06-19 |
1982-02-23 |
Nelson Research & Development Co. |
Vehicle composition containing 1-substituted azacycloalkan-2-ones
|
|
US4557934A
(en)
|
1983-06-21 |
1985-12-10 |
The Procter & Gamble Company |
Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
|
|
US4524008A
(en)
|
1983-12-16 |
1985-06-18 |
E. I. Du Pont De Nemours And Company |
Controlled initiation chromium dioxide synthesis
|
|
US4568343A
(en)
|
1984-10-09 |
1986-02-04 |
Alza Corporation |
Skin permeation enhancer compositions
|
|
US5023252A
(en)
*
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
|
US4783450A
(en)
|
1987-04-13 |
1988-11-08 |
Warner-Lambert Company |
Use of commercial lecithin as skin penetration enhancer
|
|
US5001139A
(en)
*
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
|
US4992445A
(en)
*
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
|
DE3802996A1
(de)
*
|
1988-02-02 |
1989-08-10 |
Cassella Ag |
Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen
|
|
US5424399A
(en)
*
|
1988-06-28 |
1995-06-13 |
The Children's Medical Center Corporation |
Human CR3α/β heterodimers
|
|
US5149780A
(en)
*
|
1988-10-03 |
1992-09-22 |
The Scripps Research Institute |
Peptides and antibodies that inhibit integrin-ligand binding
|
|
WO1992003473A1
(en)
*
|
1990-08-27 |
1992-03-05 |
Cetus Corporation |
Cd18 peptide medicaments for the treatment of disease
|
|
US5288854A
(en)
*
|
1990-11-28 |
1994-02-22 |
Center For Blood Research, Inc. |
Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
|
|
DE69229275T2
(de)
*
|
1991-10-04 |
1999-12-30 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville |
Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
|
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
US6162432A
(en)
*
|
1991-10-07 |
2000-12-19 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
CA2131190C
(en)
*
|
1992-02-28 |
2008-08-12 |
Peter E. Lipsky |
Compositions and methods for the treatment of thermal injury
|
|
US5298492A
(en)
*
|
1992-08-04 |
1994-03-29 |
Schering Corporation |
Diamino acid derivatives as antihypertensives
|
|
AU687755B2
(en)
*
|
1992-08-21 |
1998-03-05 |
Genentech Inc. |
Method for treating an LFA-1-mediated disorder
|
|
US5397791A
(en)
*
|
1993-08-09 |
1995-03-14 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
PT656348E
(pt)
*
|
1993-12-03 |
2000-10-31 |
Hoffmann La Roche |
Derivados do acido acetico como medicamentos
|
|
US5470953A
(en)
*
|
1993-12-23 |
1995-11-28 |
Icos Corporation |
Human β2 integrin α subunit
|
|
US6228383B1
(en)
|
1994-03-03 |
2001-05-08 |
Gs Development Ab |
Use of fatty acid esters as bioadhesive substances
|
|
WO1995028170A1
(en)
|
1994-04-19 |
1995-10-26 |
The University Of Kansas |
Icam-1/lfa-1 short-chain peptides and method of using same
|
|
US5585359A
(en)
*
|
1994-09-29 |
1996-12-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
DK0710657T3
(da)
*
|
1994-11-02 |
1999-05-25 |
Merck Patent Gmbh |
Adhæsionsreceptor-antagonister
|
|
US5747035A
(en)
|
1995-04-14 |
1998-05-05 |
Genentech, Inc. |
Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
|
|
WO1997005185A2
(en)
|
1995-07-28 |
1997-02-13 |
Focal, Inc. |
Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents
|
|
IL129344A0
(en)
*
|
1996-11-27 |
2000-02-17 |
Du Pont Pharm Co |
Novel integrin receptor antagonists
|
|
NZ502872A
(en)
|
1997-08-28 |
2002-10-25 |
Novartis Ag |
Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases
|
|
US6541606B2
(en)
*
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
|
JP2002509881A
(ja)
|
1998-03-27 |
2002-04-02 |
ジェネンテク・インコーポレイテッド |
Ｃｄ１１／ｃｄ１８接着レセプター媒介疾患の治療用アンタゴニスト
|
|
US6331640B1
(en)
|
1998-10-13 |
2001-12-18 |
Hoffmann-La Roche Inc. |
Diaminopropionic acid derivatives
|
|
US6670321B1
(en)
*
|
1998-12-30 |
2003-12-30 |
The Children's Medical Center Corporation |
Prevention and treatment for retinal ischemia and edema
|
|
WO2000040262A1
(en)
*
|
1999-01-05 |
2000-07-13 |
The Flinders University Of South Australia |
Novel agents and methods for treatment and diagnosis of ocular disorders
|
|
EP1028114A1
(en)
*
|
1999-02-13 |
2000-08-16 |
Aventis Pharma Deutschland GmbH |
Novel guanidine derivatives as inhibitors of cell adhesion
|
|
US6294522B1
(en)
*
|
1999-12-03 |
2001-09-25 |
Cv Therapeutics, Inc. |
N6 heterocyclic 8-modified adenosine derivatives
|
|
US6605597B1
(en)
*
|
1999-12-03 |
2003-08-12 |
Cv Therapeutics, Inc. |
Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
|
|
PT1237575E
(pt)
*
|
1999-12-14 |
2008-11-17 |
Genentech Inc |
Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide
|
|
DE60110396T2
(de)
|
2000-01-14 |
2006-01-19 |
Larson, Richard S., Albuquerque |
Peptidische inhibitoren der lfa-1/icam-1 interaktion
|
|
US6515124B2
(en)
|
2000-02-09 |
2003-02-04 |
Hoffman-La Roche Inc. |
Dehydroamino acids
|
|
JP2003532703A
(ja)
*
|
2000-05-05 |
2003-11-05 |
ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） |
新規アミノ酸誘導体及びその医薬としての使用
|
|
EP1294704A1
(en)
*
|
2000-06-29 |
2003-03-26 |
Abbott Laboratories |
Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
|
|
PE20020420A1
(es)
*
|
2000-10-02 |
2002-06-27 |
Novartis Ag |
Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1)
|
|
US6653478B2
(en)
*
|
2000-10-27 |
2003-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
|
|
GB0028367D0
(en)
*
|
2000-11-21 |
2001-01-03 |
Celltech Chiroscience Ltd |
Chemical compounds
|
|
WO2002059114A1
(en)
*
|
2000-11-28 |
2002-08-01 |
Genentech, Inc. |
Lfa-1 antagonist compounds
|
|
ATE348829T1
(de)
*
|
2001-02-06 |
2007-01-15 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
|
|
AU2002250236A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
|
US6391290B1
(en)
*
|
2001-03-21 |
2002-05-21 |
Schering-Plough Healthcare Products, Inc. |
Skin care compositions
|
|
US6872382B1
(en)
*
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
JP4583751B2
(ja)
*
|
2001-06-06 |
2010-11-17 |
アベンティス・フアーマ・リミテッド |
炎症性疾患の治療に使用するための置換されたテトラヒドロイソキノリン
|
|
WO2003009740A2
(en)
*
|
2001-07-24 |
2003-02-06 |
Biogen Idec Ma Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
|
RU26988U1
(ru)
|
2002-05-06 |
2003-01-10 |
Закрытое акционерное общество "ДУКС-ЛИЗИНГ" |
Кондуктор для сверления отверстий
|
|
AU2003248627A1
(en)
*
|
2002-06-06 |
2003-12-22 |
Dana-Farber Cancer Institute |
Compounds or agents that inhibit and induce the formation of focal microvessel dilatations
|
|
US7785578B2
(en)
*
|
2002-10-11 |
2010-08-31 |
Aciont, Inc. |
Non-invasive ocular drug delivery
|
|
CA2544678C
(en)
*
|
2003-11-05 |
2013-12-31 |
Sunesis Pharmaceuticals, Inc. |
Modulators of cellular adhesion
|
|
CN1902195B
(zh)
*
|
2003-11-05 |
2016-03-23 |
萨可德生物科学公司 |
细胞粘着调节剂
|
|
WO2005065668A2
(en)
*
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
RU2006146939A
(ru)
*
|
2004-06-09 |
2008-07-20 |
Дженентек |
Способ лечения кольцевидной гранулемы или саркоида
|
|
AU2005266997A1
(en)
*
|
2004-07-22 |
2006-02-02 |
Wyeth |
Method for treating nervous system disorders and conditions
|
|
DK2444079T3
(en)
*
|
2005-05-17 |
2017-01-30 |
Sarcode Bioscience Inc |
Compositions and Methods for the Treatment of Eye Diseases
|
|
ES2830024T3
(es)
*
|
2007-10-19 |
2021-06-02 |
Novartis Ag |
Composiciones y métodos para el tratamiento del edema macular
|
|
US20090257957A1
(en)
*
|
2008-04-15 |
2009-10-15 |
John Burnier |
Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
|
|
WO2009139817A2
(en)
*
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
WO2009128932A1
(en)
*
|
2008-04-15 |
2009-10-22 |
Sarcode Corporation |
Delivery of lfa-1 antagonists to the gastrointestinal system
|
|
WO2011050175A1
(en)
*
|
2009-10-21 |
2011-04-28 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
KR20200108932A
(ko)
*
|
2012-07-25 |
2020-09-21 |
에스에이알코드 바이오사이언스 인코포레이티드 |
Lfa-1 저해제 및 그의 다형체
|